Affordable Access

Publisher Website

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.

Authors
Type
Published Article
Journal
Cancer
1097-0142
Publisher
Wiley Blackwell (John Wiley & Sons)
Publication Date
Volume
120
Issue
16
Pages
2457–2463
Identifiers
DOI: 10.1002/cncr.28726
PMID: 24752410
Source
Medline
Keywords
  • Everolimus
  • Neuroendocrine Tumor
  • Octreotide Long-Acting Repeatable

Abstract

The everolimus-octreotide LAR combination was active and well tolerated in these previously treated patients with advanced NETs, suggesting a possible role as first-line treatment in patients with NET.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments